Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 530 participants.
Also called NCT01045707
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 530 participants
- Sponsor
- Registry
-
NCT01045707 -
2009-011271-78 -
2009-015839-33
-
- Other papers using this trial's data
- Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, India, Poland, Puerto Rico, Russia, South Korea, Spain, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01045707. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results posted on 2015-11-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
- Acronym
- BOOST™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01045707- Content hash
bbe0fd2c02610e176972c2dd88c7f786e33afecb5609bc765c7dbf149a0c698e